Biomerica reported QQ1 2025 revenue of $1.807 million, delivering a modest year-over-year gain of 5.5% but a sharp sequential jump of approximately 61.9% from the prior quarter, signaling a potential early-season rebound or favorable mix within a very small base. Despite the top-line uptick, profitability remained extensively negative with EBITDA of $(1.271) million and net income of $(1.316) million, translating to an EPS of $(0.0782). The quarter highlighted a lean gross profit of $289k on $1.808 million of revenue, implying a gross margin of roughly 16.0%, while operating expenses of $1.657 million and R&D of $0.297 million kept the company in a loss position.
Cash-flow dynamics remained challenging, with operating cash flow of $(1.344) million and free cash flow of $(1.344) million, contributing to a trailing cash balance of $2.82 million and a net cash position that dwarfs short-term debt. The balance sheet depicts a modest asset base (total assets of $7.87 million) with liabilities of about $2.52 million and equity of $5.35 million; retained earnings are deeply negative at $(49.51) million, underscoring a long-running cumulative deficit typical of a development-stage healthcare technology company.
Management commentary is not captured in the provided transcript dataset for QQ1 2025, limiting the ability to quote specific remarks. Nonetheless, the company’s near-term emphasis appears to remain on optimizing product mix to improve gross margins, preserving liquidity to fund pipeline advancement (including InFoods IBS therapy, Helicobacter pylori diagnostics, and COVID-related initiatives), and pursuing strategic partnerships or licensing that could accelerate commercial adoption. Absent explicit quarterly guidance, investors should monitor operating expense control, milestone-driven pipeline progress, and any potential financing actions to sustain liquidity while advancing core product development.